Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

(2013) Dan Stark et al.   LANCET ONCOLOGY

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

(2012) Marcela G. del Carmen et al.   GYNECOLOGIC ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive value of loci in VEGF pathway genes in bevacizumab treatment

(2012) Mauro Moroni   LANCET ONCOLOGY

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

(2012) Diether Lambrechts et al.   LANCET ONCOLOGY

Improved curve fits to summary survival data: application to economic evaluation of health technologies

(2011) Martin W Hoyle et al.   BMC Medical Research Methodology

Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab

(2011) Satoshi Matsusaka et al.   CANCER

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

(2011) Gilberto de Lima Lopes et al.   CANCER

Will Evidence Ever Be Sufficient to Resolve the Challenge of Cost Containment?

(2011) Arthur L. Caplan   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis

(2011) David E. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficient and Cost Effective Population Resequencing by Pooling and In-Solution Hybridization

(2011) Vikas Bansal et al.   PLoS One

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

(2010) Ernest S. Han et al.   GYNECOLOGIC ONCOLOGY

Bevacizumab toxicities and their management in ovarian cancer

(2010) Leslie M. Randall et al.   GYNECOLOGIC ONCOLOGY

Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Müllerian Tumors

(2009) Richard T. Penson et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

(2009) N. Mittmann et al.   JNCI-Journal of the National Cancer Institute

An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard

(2008) Chris P. Lee et al.   VALUE IN HEALTH

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

(2007) Agustin A. Garcia et al.   JOURNAL OF CLINICAL ONCOLOGY